Get ready for groundbreaking innovation in healthcare solutions.
We’re developing advanced therapies to address chronic liver diseases like NAFLD and NASH like:
Revolutionary Therapies: Cutting-edge peptidomimetic treatments targeting liver inflammation, fibrosis, and metabolism.
Innovative Research: Leveraging SOCS1-derived peptides for safer, more effective therapeutic solutions.
Commitment to Patients: Solutions designed to improve quality of life for those with diabetes, obesity, and liver conditions.
Biomedic Startup
announcement
New therapeutic peptides slow progression of fatty liver disease of metabolic origin.
A new family of therapeutic peptides has demonstrated protective effects against metabolic dysfunction-associated fatty liver disease (MASLD)
CIBER research group
